SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of PepGen Inc. (NASDAQ: PEPG). The investigation focuses on whether PepGen or certain of its executives violated federal securities laws.
What if I purchased PepGen securities?
If you purchased PepGen securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
Background of the investigation
On March 5, 2026, PepGen disclosed that the U.S. Food and Drug Administration (“FDA”) had placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 multiple ascending dose, randomized, placebo-controlled clinical trial of PGN-EDODM1. The Company stated that the clinical hold was imposed due to concerns related to previously submitted preclinical pharmacology and toxicology studies.
Following this announcement, PepGen’s stock price declined sharply during intraday trading on March 5, 2026, as investors reacted to the regulatory development and the uncertainty surrounding the FREEDOM2 clinical program.
In light of this disclosure, Johnson Fistel is investigating whether PepGen complied with the federal securities laws. If you suffered losses from your investment in PepGen stock, contact Johnson Fistel.
About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.
Achievements
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. This recognition reflects the firm’s effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel. This marks the eighth time the firm has been recognized as a top plaintiffs’ securities law firm in the United States, based on the total dollar value of final recoveries.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | jimb@johnsonfistel.com | fjohnson@johnsonfistel.com
